← All trials
NCT05559359
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 18, 2022
- Primary completion
- Jul 15, 2024
- Completion date
- Aug 15, 2025
- First posted
- Sep 29, 2022
- Last posted
- Dec 9, 2022
- Enrollment
- 300
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Eli LillyLead sponsor
- Eli LillyStudy director
- Dermira, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.